Ten years ago this conversation did not exist for most Indian cancer patients. Surgery. Chemotherapy. Radiation. That was the list. For many cancers in advanced stages, those options ran out quickly, and the conversations that followed were about time, not treatment. That has changed, not for every patient, not for every cancer type, but meaningfully, measurably, in ways that are showing up in real outcomes at specialised centres across India. Immunotherapy for cancer in India is no longer a clinical trial. It is a standard of care for certain cancers and an active option for many more. What it is, how it works, and who it actually helps that is what this piece covers. 

The Biology Behind It 

Cancer survives by hiding. The immune system is built to find and destroy abnormal cells, including cancer cells. It does this continuously, and in most people most of the time, it succeeds. Cancer that develops into a detectable tumour has already done something remarkable it has learnt to fool the immune system into leaving it alone. 

It does this through proteins on its surface that send signals to immune cells saying, 'Do not attack this.' The immune cell reads the signal, stands down, and the cancer continues to grow. The immune system is not broken. It is being actively deceived. 

Immunotherapy removes the deception. It does not attack cancer directly the way chemotherapy does. It removes the mechanism cancer uses to hide, and then the immune system, suddenly able to see what was hidden, does what it was already equipped to do. 

This is why the side effect profile of immunotherapy is different from chemotherapy. The toxicity is not from drugs killing cells indiscriminately. It comes from an immune system that, once activated, can sometimes attack healthy tissue alongside cancer tissue. The management of that immune activation is one of the clinical skills that distinguishes an experienced immunotherapy team from one that simply prescribes the drugs. 

The Main Types Available in India 

Checkpoint inhibitors are the most widely used immunotherapies in clinical practice right now. Cancer cells exploit checkpoint proteins on their surface proteins that tell immune cells to stop. Checkpoint inhibitor drugs block those proteins, releasing the immune system from the brake that cancer has applied. 

PD-L1 immunotherapy is the specific checkpoint pathway that has produced the most significant clinical results across multiple cancer types. PD-L1 is a protein on tumour cell surfaces that binds to PD-1 receptors on immune cells and suppresses their attack. Drugs that block this binding, such as pembrolizumab, nivolumab, and atezolizumab, among others, have changed treatment outcomes in lung cancer, bladder cancer, melanoma, certain head and neck cancers, and several others. 

Before PD-L1 immunotherapy in India is recommended, the tumour is tested for PD-L1 expression. Higher expression levels generally indicate a better likelihood of response, though the relationship is not absolute, and full molecular tumour profiling provides more complete information than PD-L1 expression alone. 

Monoclonal antibodies are engineered proteins that target specific molecules on cancer cell surfaces, marking them for immune destruction or blocking proteins cancer cells depend on for survival. 

CAR-T cell therapy takes a patient's own T-cells, immune cells, modifies them in a laboratory to recognise a specific cancer target, multiplies them, and infuses them back. The results in relapsed blood cancers, particularly ALL and diffuse large B-cell lymphoma, have been among the most dramatic outcomes in modern oncology. Patients who had exhausted every conventional option were achieving complete remission. These are not anecdotes. They are documented outcomes in published clinical data and in the clinical experience of centers that have been delivering CAR-T therapy long enough to accumulate real follow up. 

Cancer Immunotherapy Success Stories India — What Real Outcomes Look Like 

Cancer immunotherapy success stories in India come from patients across the country whose tumours responded to treatment that conventional options could not achieve. 

Lung cancer patients with high PD-L1 expression who had progressed through chemotherapy achieved sustained responses on checkpoint inhibitor therapy measured in years, not months. Melanoma patients with metastatic disease are among the most historically resistant presentations in oncology, experiencing durable remission on combination checkpoint inhibitor protocols. Blood cancer patients who relapsed after multiple chemotherapy lines are achieving complete remission through CAR-T therapy. 

These outcomes are real. They are also not guaranteed. Immunotherapy does not work for every patient. Response rates vary significantly by cancer type, molecular profile, how many prior treatments a patient has received, and individual immune system characteristics. This is the central reason that proper molecular testing and specialist assessment before treatment selection are not optional it is what determines whether immunotherapy is the right tool for a specific patient's specific tumour. 

Choosing immunotherapy for a cancer type or molecular profile where the evidence of benefit is limited does not produce immunotherapy outcomes. It produces a delay of the treatment that might actually help. 

What a Facility Needs to Deliver Immunotherapy Properly 

Immunotherapy for cancer in India delivered correctly requires things that not every facility claiming to offer it actually provides. 

Molecular diagnostic capability is the ability to profile tumour tissue at the genetic and protein expression level before treatment decisions are made. PD-L1 expression testing. Tumour mutational burden analysis. Microsatellite instability testing. Without this information, treatment selection is incomplete regardless of how experienced the oncologist is. 

Clinical experience managing immune related adverse events. The side effects of checkpoint inhibitors are mechanistically different from chemotherapy toxicity they involve the immune system attacking healthy tissue in the gut, lungs, liver, skin, endocrine system, and glands. Recognising these events early, distinguishing them from disease progression or infection, and managing them appropriately requires specific clinical experience that comes from treating enough patients to have seen the full range of presentations. 

Multidisciplinary tumour board review before treatment begins. Oncology, pathology, radiology, and relevant surgical specialities assessing each case together, not a single physician deciding alone. 

IOCI — What This Looks Like in Practice 

At IOCI, every patient considered for PD-L1 immunotherapy goes through molecular tumour profiling before a recommendation is made. Treatment selection is driven by what the tumour's biology actually shows, not by what is newest or most available. 

Cancer immunotherapy success stories in India from IOCI patients reflect the result of this approach proper selection, correct sequencing within the overall treatment plan, and active management through the full treatment course. Not patients started on immunotherapy and then left to manage the consequences of immune activation without specialist oversight. 

Immunotherapy has changed what is possible. Getting to those outcomes requires getting the process right from the beginning. Patients may want to think about going to a specialised oncology centre with experts in many fields.